Does 11q23/MLL rearrangement confer a poor prognosis in infants with acute lymphoblastic leukemia?
The 11q23/MLL involvement of blast cells identifies a major subgroup of infant ALL cases that require an innovative treatment approach. Infants who lack this genetic abnormality have an intermediate prognosis and could be treated accordingly on risk-directed protocols.
The results of this investigation do not support the use of dexamethasone for treatment of HELLP syndrome.